RE: Hearhrow Airport to use Rapid Antibody testing.30 May 2020 18:14
The Company have near term plans to scale up to a production capacity of over 4 million tests per month. See message from twitter company DM...
“Our current capacity for lateral flow tests at Alva is 100,000 tests per week. We are currently in the process of increasing that to 200,000 tests per week and looking at options to further increase to 500,000 tests per week.
Our capacity in Littleport is currently just under 50,000 tests per day. We are currently looking to increase that to 100,000 per day.
We only have two manufacturing sites.”
If we apply a conservative retail price of £6 per test and a conservative margin (for MTKs) of 40% then that gives an annualized free profit of £120,000,000.
Apply a conservative, attractive P/E ratio of 10 or so and that’s the valuation in twelve months or so.
This assumes, as confirmed in interview and RNS that the tests are finished design wise and WILL be produced and the leaked DM article was correct and the Gov will order an initial 50 mill from the consortium. This will give Omega the funding required to implement the expansion plans and fully monetize the test manufacture to full capacity.
Massive global market, unique product, manufacturing capacity approaching 50 million per year at £2-3each min clear profit.
Robert’s yer mother’s brother. :)